CERSCERUS CORP

Nasdaq cerus.com


$ 2.13 $ -0.09 (-4.05 %)    

Wednesday, 07-Aug-2024 12:17:28 EDT
QQQ $ 443.91 $ -1.67 (-0.37 %)
DIA $ 392.03 $ -0.49 (-0.12 %)
SPY $ 527.03 $ -0.76 (-0.14 %)
TLT $ 96.33 $ 0.29 (0.3 %)
GLD $ 221.36 $ -0.65 (-0.29 %)
$ 2.19
$ 2.22
$ 2.12 x 300
$ 2.14 x 259
$ 2.13 - $ 2.22
$ 1.21 - $ 2.59
860,103
na
405.11M
$ 1.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 03-05-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 03-01-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-22-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 08-03-2021 06-30-2021 10-Q
14 05-04-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 10-29-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-05-2020 03-31-2020 10-Q
19 02-21-2020 12-31-2019 10-K
20 10-30-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 02-27-2019 12-31-2018 10-K
24 11-01-2018 09-30-2018 10-Q
25 08-02-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 03-08-2018 12-31-2017 10-K
28 11-03-2017 09-30-2017 10-Q
29 08-04-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 03-08-2017 12-31-2016 10-K
32 11-04-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-06-2016 03-31-2016 10-Q
35 03-09-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-07-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 03-16-2015 12-31-2014 10-K
40 11-07-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cerus-q2-2024-gaap-eps-003-beats-004-estimate-sales-45079m-miss-46627m-estimate

Cerus (NASDAQ:CERS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 p...

 cantor-fitzgerald-maintains-overweight-on-cerus-raises-price-target-to-4

Cantor Fitzgerald analyst Ross Osborn maintains Cerus (NASDAQ:CERS) with a Overweight and raises the price target from $3 to...

 craig-hallum-initiates-coverage-on-cerus-with-buy-rating-announces-price-target-of-5

Craig-Hallum initiates coverage on Cerus (NASDAQ:CERS) with a Buy rating and announces Price Target of $5.

 perion-network-cuts-sales-outlook-joins-range-resources-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

U.S. stock futures were mixed this morning, with the Dow futures falling by around 10 points on Monday.

 cerus-corporation-announces-fda-approval-of-extended-shelf-life-for-intercept-platelet-processing-sets-doubling-previous-shelf-life

Cerus Corporation (NASDAQ:CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-mon...

 cathie-woods-ark-invest-sells-another-tranche-of-block-shares-even-as-bitcoin-price-stages-a-recovery

On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc (NYSE:SQ) amidst Bitcoin (CR...

 why-blood-components-focused-cerus-stock-is-rising-tuesday

Cerus reports results from the ReCePI Phase 3 trial for INTERCEPT Red Blood Cells, meeting the primary efficacy endpoint in car...

Core News & Articles
Market-Moving News for March 19th
03/19/2024 12:41:16

CERS: 64% | Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; S...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION